Form 4 for FENC FENNEC PHARMACEUTICALS INC.
Accepted 2023-11-09 00:00:00 ET · period of report 2023-11-08 · accession 0001415889-23-014958 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-11-09 | 2023-11-08 | FENC | Raykov Rosty | CEO, Dir | S - Sale | $7.76 | -25.0K | 290.6K | -8% | -$194.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares | 2023-11-08 | S | D | 7,995 | $7.90 | 282,587 | D | — | — | (F2) Shares were the results of options granted on November 20, 2012, with a strike price of $1.05. Price of sold shares is an average. |
| 2 | Common | Common shares | 2023-11-08 | S | D | 17,049 | $7.69 | 290,582 | D | — | — | (F1) Shares were the results of an option exercise on August 20, 2018, with a strike price of $1.44. Price of sold shares is an average. |